Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

NCRI 2019 | Aberrrant transcriptional programming in AML

Constanze Bonifer • 8 Nov 2019
NCRI 2019
Acute Myeloid Leukemia Leukemia

Constanze Bonifer, PhD, University of Birmingham, Birmingham, UK, talks about sub-type specific aberrant transcriptional programming in acute myeloid leukemia (AML). Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Constanze Bonifer

The impact of various chromosomal abnormalities observed in AML & insights into RUNX1-ETO
3:48
The impact of various chromosomal abnormalities observed in AML & insights into RUNX1-ETO
Constanze Bonifer • 16 Mar 2023
The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML
3:15
The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML
Constanze Bonifer • 16 Mar 2023
Using transcriptional network analysis to better understand AML development and evolution
4:09
Using transcriptional network analysis to better understand AML development and evolution
Constanze Bonifer • 16 Mar 2023
The molecular impact of RUNX1 mutations in AML
3:18
The molecular impact of RUNX1 mutations in AML
Constanze Bonifer • 16 Mar 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Constanze Bonifer • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Constanze Bonifer • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Constanze Bonifer • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Constanze Bonifer • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals